Albany downgraded by Jefferies to underperform

Albany Molecular Research Inc. was downgraded by Jefferies & Co. analyst David Windley to underperform from hold, and the price target on the stock was reduced to $10 per share from $12, following the announced launch of generic Allegra tablets by Barr Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. Albany shares Tuesday were down $3.97, or 23.41%, at $12.99 on volume of 1,735,455 shares versus the three-month running average of 218,314 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.